Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
-
- Satoshi Yamashita
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Atsushi Sakamoto
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Satoshi Shoji
- Department of Cardiology, Hino Municipal Hospital, Hino 1910062, Japan
-
- Yoshitaka Kawaguchi
- Department of Cardiology, Seirei Mikatahara Hospital, Hamamatsu 4338558, Japan
-
- Yasushi Wakabayashi
- Department of Cardiology, Seirei Mikatahara Hospital, Hamamatsu 4338558, Japan
-
- Masaki Matsunaga
- Department of Cardiology, Iwata City Hospital, Iwata 4388550, Japan
-
- Kiyohisa Suguro
- Department of Cardiology, Fujinomiya City Hospital, Fujinomiya 4180076, Japan
-
- Yuji Matsumoto
- Department of Cardiology, Kikugawa City Hospital, Kikugawa 4390022, Japan
-
- Hiroyuki Takase
- Department of Internal Medicine, Enshu Hospital, Hamamatsu 4300929, Japan
-
- Tomoya Onodera
- Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka 4208630, Japan
-
- Kei Tawarahara
- Department of Cardiology, Hamamatsu Red Cross Hospital, Hamamatsu 4348533, Japan
-
- Masahiro Muto
- Department of Cardiology, Hamamatsu Medical Center, Hamamatsu 4328580, Japan
-
- Yasutaka Shirasaki
- Shirasaki Clinic, Kuki 3460031, Japan
-
- Hideki Katoh
- Department of Cardiology, Kosai General Hospital, Kosai 4310431, Japan
-
- Makoto Sano
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Kenichiro Suwa
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Yoshihisa Naruse
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Hayato Ohtani
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Masao Saotome
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Tsuyoshi Urushida
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
-
- Shun Kohsaka
- Department of Cardiology, Keio University School of Medicine, Tokyo 1608582, Japan
-
- Eisaku Okada
- Department of Faculty of Social Policy and Administration, Hosei University, Tokyo 1028160, Japan
-
- Yuichiro Maekawa
- Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan
書誌事項
- 公開日
- 2023-05-09
- 資源種別
- journal article
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.3390/jcdd10050204
- 公開者
- MDPI AG
説明
<jats:p>Background: The guideline-recommended low-density lipoprotein cholesterol target level of <70 mg/dL may not be achieved with statin administration in some patients with acute coronary syndrome (ACS). Therefore, the proprotein convertase subtilisin-kexin type 9 (PCSK9) antibody can be added to high-risk patients with ACS. Nevertheless, the optimal duration of PCSK9 antibody administration remains unclear. Methods and Results: Patients were randomized to receive either 3 months of lipid lowering therapy (LLT) with the PCSK9 antibody followed by conventional LLT (with-PCSK9-antibody group) or 12 months of conventional LLT alone (without-PCSK9-antibody group). The primary endpoint was the composite of all-cause death, myocardial infarction, stroke, unstable angina, and ischemia-driven revascularization. A total of 124 patients treated with percutaneous coronary intervention (PCI) were randomly assigned to the two groups (n = 62 in each). The primary composite outcome occurred in 9.7% and 14.5% of the patients in the with- and without-PCSK9-antibody groups, respectively (hazard ratio: 0.70; 95% confidence interval: 0.25 to 1.97; p = 0.498). The two groups showed no significant differences in hospitalization for worsening heart failure and adverse events. Conclusions: In ACS patients who underwent PCI, short-term PCSK9 antibody therapy with conventional LLT was feasible in this pilot clinical trial. Long-term follow-up in a larger scale clinical trial is warranted.</jats:p>
収録刊行物
-
- Journal of Cardiovascular Development and Disease
-
Journal of Cardiovascular Development and Disease 10 (5), 204-, 2023-05-09
MDPI AG
